Immunological and inflammatory functions of the interleukin-1 family

Annual Review of Immunology

Volumn 27, Issue , 2009, Pages 519-550

  Dinarello, Charles A ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Autoinflammatory; Caspase 1; Cytokine; Host defense; Inflammasome

Indexed keywords

CELL ADHESION MOLECULE; COMPLEMENT COMPONENT C5A; CRYOPYRIN; CYCLOOXYGENASE 2; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 1 DERIVATIVE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 18; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 1F10; INTERLEUKIN 1F5; INTERLEUKIN 1F6; INTERLEUKIN 1F7; INTERLEUKIN 1F8; INTERLEUKIN 1F9; INTERLEUKIN 33; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NITRIC OXIDE SYNTHASE; PURINERGIC P2X7 RECEPTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ADULT ONSET STILL DISEASE; ANTIBODY PRODUCTION; ANTIGEN RECOGNITION; ARTHRALGIA; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; AUTOINFLAMMATORY DISEASE; B LYMPHOCYTE; BEHCET DISEASE; BIOLOGICAL ACTIVITY; BLAU SYNDROME; BLOOD CLOT; CARCINOGENESIS; CELL DIFFERENTIATION; CELL INFILTRATION; CELL STIMULATION; CHILL; CINCA SYNDROME; COLD EXPOSURE; COLD URTICARIA; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISSOCIATION; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; FAMILIAL MEDITERRANEAN FEVER; FATIGUE; FEVER; GENETIC ANALYSIS; GOUT; GROWTH RETARDATION; HOST RESISTANCE; HUMAN; HYPERPHAGIA; HYPOXIA; IMMUNE RESPONSE; IMMUNOREACTIVITY; INFLAMMATION; INNATE IMMUNITY; JUVENILE RHEUMATOID ARTHRITIS; LEUKOCYTOSIS; MACROPHAGE ACTIVATION SYNDROME; METABOLIC SYNDROME X; MEVALONIC ACIDURIA; MUCKLE WELLS SYNDROME; NATURAL KILLER CELL; NEUTROPHIL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OLIGOMERIZATION; PAPA SYNDROME; PERICARDITIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; RASH; REGULATORY MECHANISM; REVIEW; SCHNITZLER SYNDROME; SINGLE NUCLEOTIDE POLYMORPHISM; STEM CELL; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; THROMBOCYTE ACTIVATION; THYMOCYTE; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; X RAY CRYSTALLOGRAPHY;

ANIMALS; B-LYMPHOCYTES; CARRIER PROTEINS; CASPASE 1; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INTERLEUKIN-1; RECEPTORS, INTERLEUKIN-1; RECEPTORS, PURINERGIC P2; RECEPTORS, PURINERGIC P2X7; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, HELPER-INDUCER; TOLL-LIKE RECEPTORS;

EID: 62649139025     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.021908.132612     Document Type: Review

References (169)

1. Sharma S, Kulk N, Nold MF, Graf R, Kim SH, et al. 2008. The IL-1 family member 7b translocates to the nucleus and down-regulates proinflammatory cytokines. J. Immunol. 180:5477-82
2. Costelloe C, Watson M, Murphy A, McQuillan K, Loscher C, et al. 2008. IL-1F5 mediates antiinflammatory activity in the brain through induction of IL-4 following interaction with SIGIRR/TIR8. J. Neurochem. 105:1960-69
3. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, et al. 2005. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23:479-90
4. Werman A,Werman-Venkert R, White R, Lee JK,Werman B, et al. 2004. The precursor form of IL-1α is an intracrine proinflammatory activator of transcription. Proc. Natl. Acad. Sci. USA 101:2434-39
5. Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, et al. 2007. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc. Natl. Acad. Sci. USA 104:282-87
6. Colotta F, Re F, Muzio M, Bertini R, Polentarutti N, et al. 1993. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 261:472-75
7. Wald D, Qin J, Zhao Z, Qian Y, Naramura M, et al. 2003. SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat. Immunol. 4:920-27
8. Garlanda C, Riva F, Polentarutti N, Buracchi C, Sironi M, et al. 2004. Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family. Proc. Natl. Acad. Sci. USA 101:3522-26
9. Novick D, Kim S-H, Fantuzzi G, Reznikov L, Dinarello CA, Rubinstein M. 1999. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 10:127-36
10. Emsley HC, Smith CJ, Georgiou RF, Vail A, Hopkins SJ, et al. 2005. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J. Neurol. Neurosurg. Psychiatry 76:1366-72
11. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. 2005. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 201:1479-86
12. Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA. 2005. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum. 52:1794-803
13. Economides AN, Carpenter LR, Rudge JS, Wong V, Koehler-Stec EM, et al. 2003. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat. Med. 9:47-52
14. Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, et al. 2008. Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 58:2443-52
15. Mandrup-Poulsen T, Bendtzen K, Nerup J, Dinarello CA, Svenson M, Nielsen JH. 1986. Affinitypurified human interleukin I is cytotoxic to isolated islets of Langerhans. Diabetologia 29:63-67
16. Bendtzen K, Mandrup-Poulsen T, Nerup J, Nielsen JH, Dinarello CA, Svenson M. 1986. Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science 232:1545-47
17. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, et al. 2007. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356:1517-26
18. Donath M, Whitmore J, Bauer R, Scannon P,Weder C, et al. 2008. Xoma 052, an anti-IL-1b antibody, in a double-blind, placebo-controlled, dose-escalation study of the safety and pharmacokinetics in patients with type 2 diabetes mellitus, a new approach to therapy. Diabetologia 51:433 (Abstr.)
19. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, et al. 2002. Glucose-induced beta cell production of IL-1β contributes to glucotoxicity in human pancreatic islets. J. Clin. Invest. 110:851-60
20. Mazodier K, Marin V, Novick D, Farnarier C, Robitail S, et al. 2005. Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. Blood 106:3483-89
21. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. 2001. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat. Genet. 29:301-5
22. Aksentijevich I, Nowak M, Mallah M, Chae JJ, Watford WT, et al. 2002. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum. 46:3340-48
23. Aganna E, Martinon F, Hawkins PN, Ross JB, Swan DC, et al. 2002. Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum. 46:2445-52
24. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. 2004. NALP3 forms an IL-1β processing inflammasome with increased activity in Muckle-Wells auto-inflammatory disorder. Immunity 20:319-25
25. Martinon F, Tschopp J. 2007. Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ. 14:10-22
26. Netea MG, Nold-Petry CA, Nold MF, Opitz B, Van Der Meer JW, et al. 2008. Monocytes are not macrophages: differential requirement for the activation of the inflammasome for processing and release of IL-1β. Blood. In press
27. Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, et al. 2006. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition. N. Engl. J. Med. 355:581-92
28. Gattorno M, Tassi S, Carta S, Delfino L, Ferlito F, et al. 2007. Pattern of interleukin-1β secretion in response to LPS and ATP in patients with CIAS1 mutations before and after interleukin-1 blockade. Arthr. Rheumat. 56:3138-48
29. Chae JJ, Komarow HD, Cheng J, Wood G, Raben N, et al. 2003. Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol. Cell 11:591-604
30. Livneh A, Langevitz P, Shinar Y, Zaks N, Kastner DL, et al. 1999. MEFV mutation analysis in patients suffering from amyloidosis of familial Mediterranean fever. Amyloid 6:1-6
31. Simon A, Van Der Meer JW. 2007. Pathogenesis of familial periodic fever syndromes or hereditary autoinflammatory syndromes. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292:R86-98
32. Solle M, Labasi J, Perregaux DG, Stam E, Petrushova N, et al. 2001. Altered cytokine production in mice lacking P2X(7) receptors. J. Biol. Chem. 276:125-32
33. Andrei C, Margiocco P, Poggi A, Lotti LV, Torrisi MR, Rubartelli A. 2004. Phospholipases C and A2 control lysosome-mediated IL-1β secretion: implications for inflammatory processes. Proc. Natl. Acad. Sci. USA 101:9745-50
34. Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, et al. 2003. IL-1 is required for tumor invasiveness and angiogenesis. Proc. Natl. Acad. Sci. USA 100:2645-50
35. Dinarello CA. 1996. Biological basis for interleukin-1 in disease. Blood 87:2095-147
36. Dinarello CA. 2007. Mutations in cryopyrin: bypassing roadblocks in the caspase 1 inflammasome for interleukin-1β secretion and disease activity. Arthritis Rheum. 56:2817-22
37. Ali S, Huber M, Kollewe C, Bischoff SC, Falk W, Martin MU. 2007. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc. Natl. Acad. Sci. USA 104:18660-65
38. Johnson VJ, Yucesoy B, Luster MI. 2005. Prevention of IL-1 signaling attenuates airway hyperresponsiveness and inflammation in a murine model of toluene diisocyanate-induced asthma. J. Allergy Clin. Immunol. 116:851-58
39. Wang CC, Fu CL, Yang YH, Lo YC,Wang LC, et al. 2006. Adenovirus expressing interleukin-1 receptor antagonist alleviates allergic airway inflammation in a murine model of asthma. Gene. Ther. 13:1414-21
40. Nakae S, Asano M, Horai R, Iwakura Y. 2001. Interleukin-1β, but not interleukin-1α, is required for T-cell-dependent antibody production. Immunology 104:402-9
41. Antoni G, Presentini R, Perin F, Tagliabue A, Ghiara P, et al. 1986. A short synthetic peptide fragment of human interleukin 1 with immunostimulatory but not inflammatory activity. J. Immunol. 137:3201-4
42. Sutton C, Brereton C, Keogh B, Mills KH, Lavelle EC. 2006. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J. Exp. Med. 203:1685-91
43. Harris KM, Fasano A, Mann DL. 2008. Cutting edge: IL-1 controls the IL-23 response induced by gliadin, the etiologic agent in celiac disease. J. Immunol. 181:4457-60
44. Kimura A, Naka T, Kishimoto T. 2007. IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells. Proc. Natl. Acad. Sci. USA 104:12099-104
45. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. 2007. Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17-producing human T helper cells. Nat. Immunol. 8:942-49
46. Chen Z, O'Shea JJ. 2008. Th17 cells: a new fate for differentiating helperTcells. Immunol. Res. 41:87-102
47. Gracie JA, Forsey RJ, Chan WL, Gilmour A, Leung BP, et al. 1999. A proinflammatory role for IL-18 in rheumatoid arthritis. J. Clin. Invest. 104:1393-401
48. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM. 1998. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-β, PGE2, and PAF. J. Clin. Invest. 101:890-98
49. Wong PK, Egan PJ, Croker BA, O'Donnell K, Sims NA, et al. 2006. SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis. J. Clin. Invest. 116:1571-81
50. Nakae S, Saijo S, Horai R, Sudo K, Mori S, Iwakura Y. 2003. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc. Natl. Acad. Sci. USA 100:5986-90
51. Matsuki T, Nakae S, Sudo K, Horai R, Iwakura Y. 2006. Abnormal T cell activation caused by the imbalance of the IL-1/IL-1R antagonist system is responsible for the development of experimental autoimmune encephalomyelitis. Int. Immunol. 18:399-407
52. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. 2001. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev. 12:53-72
53. Konishi H, Tsutsui H, Murakami T, Yumikura-Futatsugi S, Yamanaka K, et al. 2002. IL-18 contributes to the spontaneous development of atopic dermatitis-like inflammatory skin lesion independently of IgE/stat6 under specific pathogen-free conditions. Proc. Natl. Acad. Sci. USA 99:11340-45
54. Hoshino T, Kawase Y, Okamoto M, Yokota K, Yoshino K, et al. 2001. Cutting edge: IL-18-transgenic mice: in vivo evidence of a broad role for IL-18 in modulating immune function. J. Immunol. 166:7014-18
55. Andoh T, Kishi H, Motoki K, Nakanishi K, Kuraishi Y, Muraguchi A. 2008. Protective effect of IL-18 on kainate- and IL-1β-induced cerebellar ataxia in mice. J. Immunol. 180:2322-28
56. Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, et al. 2000. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J. Exp. Med. 191:313-20
57. Nicklin MJ, Hughes DE, Barton JL, Ure JM, Duff GW. 2000. Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J. Exp. Med. 191:303-12
58. Krelin Y, Voronov E, Dotan S, Elkabets M, Reich E, et al. 2007. Interleukin-1β-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res. 67:1062-71
59. Netea MG, Joosten LA, Lewis E, Jensen DR, Voshol PJ, et al. 2006. Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nat. Med. 12:650-56
60. Mulero JJ, Pace AM, Nelken ST, Loeb DB, Correa TR, et al. 1999. IL1HY1: a novel interleukin-1 receptor antagonist gene. Biochem. Biophys. Res. Commun. 263:702-6
61. Chen C-J, Kono H, Golenbock D, Reed G, Akira S, Rock KL. 2007. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat. Med. 13:851-56
62. Lonnemann G, Engler-Blum G,Müller GA, Koch KM, Dinarello CA. 1995. Cytokines in human renal interstitial fibrosis. II. Intrinsic interleukin (IL)-1 synthesis and IL-1-dependent production of IL-6 and IL-8 by cultured kidney fibroblasts. Kidney Int. 47:845-54
63. Hurgin V, Novick D,Werman A, Dinarello CA, Rubinstein M. 2007. Antiviral and immunoregulatory activities of IFN-γ depend on constitutively expressed IL-1α. Proc. Natl. Acad. Sci. USA 104:5044-49
64. Maier JAM, Statuto M, Ragnotti G. 1994. Endogenous interleukin-1α must be transported to the nucleus to exert its activity in human endothelial cells. Mol. Cell. Biol. 14:1845-51
65. Kawaguchi Y, Nishimagi E, Tochimoto A, Kawamoto M, Katsumata Y, et al. 2006. Intracellular IL-1α-binding proteins contribute to biological functions of endogenous IL-1α in systemic sclerosis fibroblasts. Proc. Natl. Acad. Sci. USA 103:14501-6
66. Horai R, Asano M, Sudo K, Kanuka H, Suzuki M, et al. 1998. Production of mice deficient in genes for interleukin (IL)-1α, IL-1β, IL-1α/β, and IL-1 receptor antagonist shows that IL-1β is crucial in turpentine-induced fever development and glucocorticoid secretion. J. Exp. Med. 187:1463-75
67. Yin H, Morioka H, Towle CA, Vidal M, Watanabe T, Weissbach L. 2001. Evidence that HAX-1 is an interleukin-1α N-terminal binding protein. Cytokine 15:122-37
68. Hammerberg C, Arend WP, Fisher GJ, Chan LS, Berger AE, et al. 1992. Interleukin-1 receptor antagonist in normal and psoriatic epidermis. J. Clin. Invest. 90:571-83
69. Kurt-Jones EA, Beller DI, Mizel SB, Unanue ER. 1985. Identification of a membrane-associated interleukin-1 in macrophages. Proc. Natl. Acad. Sci. USA 82:1204-8
70. Kaplanski G, Farnarier C, Kaplanski S, Porat R, Shapiro L, et al. 1994. Interleukin-1 induces interleukin-8 from endothelial cells by a juxacrine mechanism. Blood 84:4242-48
71. Kamari Y,Werman-Venkert R, Shaish A,Werman A, Harari A, et al. 2007. Differential role and tissue specificity of interleukin-1αgene expression in atherogenesis and lipid metabolism. Atherosclerosis 195:31-38
72. Hacham M, Argov S, White RM, Segal S, Apte RN. 2002. Different patterns of interleukin-1α and interleukin-1β expression in organs of normal young and old mice. Eur. Cytokine Netw. 13:55-65
73. Kuida K, Lippke JA, Ku G, Harding MW, Livingston DJ, et al. 1995. Altered cytokine export and apoptosis in mice deficient in interleukin-1β converting enzyme. Science 267:2000-3
74. Kaspar RL, Gehrke L. 1994. Peripheral blood mononuclear cells stimulated with C5a or lipopolysaccharide to synthesize equivalent levels of IL-1β mRNA show unequal IL-1β protein accumulation but similar polyribosome profiles. J. Immunol. 153:277-86
75. Bufler P, Gamboni-Robertson F, Azam T, Kim SH, Dinarello CA. 2004. Interleukin-1 homologues IL-1F7b and IL-18 contain functional mRNA instability elements within the coding region responsive to lipopolysaccharide. Biochem. J. 381:503-10
76. Schindler R, Clark BD, Dinarello CA. 1990. Dissociation between interleukin-1β mRNA and protein synthesis in human peripheral blood mononuclear cells. J. Biol. Chem. 265:10232-37
77. Unlu S, Kumar A, Waterman WR, Tsukada J, Wang KZ, et al. 2007. Phosphorylation of IRF8 in a preassociated complex with Spi-1/PU.1 and nonphosphorylated Stat1 is critical for LPS induction of the IL1B gene. Mol. Immunol. 44:3364-79
78. Dinarello CA, Ikejima T, Warner SJ, Orencole SF, Lonnemann G, et al. 1987. Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J. Immunol. 139:1902-10
79. Greten FR, Arkan MC, Bollrath J, Hsu LC, Goode J, et al. 2007. NF-κB is a negative regulator of IL-1β secretion as revealed by genetic and pharmacological inhibition of IKKβ. Cell 130:918-31
80. Boeni-Schnetzler M, Thorne J, Parnaud P, Marselli L, Ehses JA, et al. 2008. Increased interleukin (IL)-1b messenger ribonucleic acid expression in B-cells of individuals with type 2 diabetes and regulation of IL-1b in human islets by glucose and autostimulation. J. Clin. Endocrinol. Metab. 93:4065-74
81. Schindler R, Ghezzi P, Dinarello CA. 1990. IL-1 induces IL-1. IV. IFN-γ suppresses IL-1 but not lipopolysaccharide-induced transcription of IL-1. J. Immunol. 144:2216-22
82. Andrei C, Dazzi C, Lotti L, Torrisi MR, Chimini G, Rubartelli A. 1999. The secretory route of the leaderless protein interleukin 1β involves exocytosis of endolysosome-related vesicles. Mol. Biol. Cell 10:1463-75
83. Gardella S, Andrei C, Costigliolo S, Olcese L, Zocchi MR, Rubartelli A. 2000. Secretion of bioactive interleukin-1β by dendritic cells is modulated by interaction with antigen specific T cells. Blood 95:3809-15
84. Perregaux DG, McNiff P, Laliberte R, Conklyn M, Gabel CA. 2000. ATP acts as an agonist to promote stimulus-induced secretion of IL-1β and IL-18 in human blood. J. Immunol. 165:4615-23
85. Qu Y, Franchi L, Nunez G, Dubyak GR. 2007. Nonclassical IL-1β secretion stimulated by P2X7 receptors is dependent on inflammasome activation and correlated with exosome release in murine macrophages. J. Immunol. 179:1913-25
86. Brough D, Rothwell NJ. 2007. Caspase-1-dependent processing of prointerleukin-1β is cytosolic and precedes cell death. J. Cell Sci. 120:772-81
87. Suzuki T, Franchi L, Toma C, Ashida H, Ogawa M, et al. 2007. Differential regulation of caspase-1 activation, pyroptosis, and autophagy via Ipaf and ASC in Shigella-infected macrophages. PLoS Pathog. 3:e111
88. Kahlenberg JM, Lundberg KC, Kertesy SB, Qu Y, Dubyak GR. 2005. Potentiation of caspase-1 activation by the P2X7 receptor is dependent on TLR signals and requires NF-κB-driven protein synthesis. J. Immunol. 175:7611-22
89. Al-Shukaili A, Al-Kaabi J, Hassan B. 2008. A comparative study of interleukin-1β production and P2x7 expression after Atp stimulation by peripheral blood mononuclear cells isolated from rheumatoid arthritis patients and normal healthy controls. Inflammation 31:84-90
90. Sluyter R, Shemon AN, Wiley JS. 2004. Glu496 to Ala polymorphism in the P2X7 receptor impairs ATP-induced IL-1 β release from human monocytes. J. Immunol. 172:3399-405
91. Sluyter R, Dalitz JG, Wiley JS. 2004. P2X7 receptor polymorphism impairs extracellular adenosine 5′-triphosphate-induced interleukin-18 release from human monocytes. Genes Immun. 5:588-91
92. Lee KH, Park SS, Kim I, Kim JH, Ra EK, et al. 2007. P2X7 receptor polymorphism and clinical outcomes in HLA-matched sibling allogeneic hematopoietic stem cell transplantation. Haematologica 92:651-57
93. Chessell IP, Hatcher JP, Bountra C, Michel AD, Hughes JP, et al. 2005. Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain 114:386-96
94. Hewinson J, Moore SF, Glover C, Watts AG, MacKenzie AB. 2008. A key role for redox signaling in rapid P2X7 receptor-induced IL-1β processing in human monocytes. J. Immunol. 180:8410-20
95. Pelegrin P, Surprenant A. 2006. Pannexin-1 mediates large pore formation and interleukin-1β release by the ATP-gated P2X7 receptor. EMBO J. 25:5071-82
96. Kanneganti TD, Lamkanfi M, Kim YG, Chen G, Park JH, et al. 2007. Pannexin-1-mediated recognition of bacterial molecules activates the cryopyrin inflammasome independent of Toll-like receptor signaling. Immunity 26:433-43
97. Derks R, Beaman K. 2004. Regeneration and tolerance factor modulates the effect of adenosine triphosphate-induced interleukin 1β secretion in human macrophages. Hum. Immunol. 65:676-82
98. Fantuzzi G, Ku G, Harding MW, Livingston DL, Sipe JD, et al. 1997. Response to local inflammation of IL-1β converting enzyme-deficient mice. J. Immunol. 158:1818-24
99. Coeshott C, Ohnemus C, Pilyavskaya A, Ross S, Wieczorek M, et al. 1999. Converting enzymeindependent release of TNFα and IL-1β from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase-3. Proc. Natl. Acad. Sci. USA 96:6261-66
100. Sugawara S, Uehara A, Nochi T, Yamaguchi T, Ueda H, et al. 2001. Neutrophil proteinase 3-mediated induction of bioactive IL-18 secretion by human oral epithelial cells. J. Immunol. 167:6568-75
101. So A, De Smedt T, Revaz S, Tschopp J. 2007. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res. Ther. 9:R28
102. Numanami H, Koyama S, Sato E, Haniuda M, Nelson DK, et al. 2003. Serine protease inhibitors modulate chemotactic cytokine production by human lung fibroblasts in vitro. Am. J. Physiol. Lung Cell. Mol. Physiol. 284:L882-90
103. Zheng H, Fletcher D, Kozak W, Jiang M, Hofmann K, et al. 1995. Resistance to fever induction and impaired acute-phase response in interleukin-1β deficient mice. Immunity 3:9-19
104. Fantuzzi G, Sacco S, Ghezzi P, Dinarello CA. 1997. Physiological and cytokine responses in interleukin-1β-deficient mice after zymosan-induced inflammation. Am. J. Physiol. 273:R400-6
105. Fantuzzi G, Zheng H, Faggioni R, Benigni F, Ghezzi P, et al. 1996. Effect of endotoxin in IL-1β-deficient mice. J. Immunol. 157:291-96
106. Faggioni R, Fantuzzi G, Fuller J, Dinarello CA, Feingold KR, Grunfeld C. 1998. IL-1β mediates leptin induction during inflammation. Am. J. Physiol. 274:R204-8
107. Dinarello CA. 2004. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr. Opin. Pharmacol. 4:378-85
108. Botsios C, Sfriso P, Furlan A, Punzi L, Dinarello CA. 2008. Reistant Behçet disease responsive to anakinra. Ann. Intern. Med. 149:284-86
109. + channel 6.2 (SUR/Kir6.2) selective potassium channel opener in human islets. Diabetes 53:1706-13
110. Hirsch E, Irikura VM, Paul SM, Hirsh D. 1996. Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice. Proc. Natl. Acad. Sci. USA 93:11008-13
111. Okamura H, Tsutsui H, Komatsu T, Yutsudo M, Hakura A, et al. 1995. Cloning of a new cytokine that induces interferon-γ. Nature 378:88-91
112. Nakamura S, Otani T, Ijiri Y, Motoda R, Kurimoto M, Orita K. 2000. IFN-γ-dependent and -independent mechanisms in adverse effects caused by concomitant administration of IL-18 and IL-12. J. Immunol. 164:3330-36
113. Sennello JA, Fayad R, Pini M, Gove ME, Ponemone V, et al. 2008. Interleukin-18, together with interleukin-12, induces severe acute pancreatitis in obese but not in nonobese leptin-deficient mice. Proc. Natl. Acad. Sci. USA 105:8085-90
114. Fantuzzi G, Reed DA, Dinarello CA. 1999. IL-12-induced IFNγ is dependent on caspase-1 processing of the IL-18 precursor. J. Clin. Invest. 104:761-67
115. Tsutsui H, Kayagaki N, Kuida K, Nakano H, Hayashi N, et al. 1999. Caspase-1-independent, Fas/Fas ligand-mediated IL-18 secretion from macrophages causes acute liver injury in mice. Immunity 11:359-67
116. Puren AJ, Fantuzzi G, Dinarello CA. 1999. Gene expression, synthesis and secretion of IL-1β and IL-18 are differentially regulated in human blood mononuclear cells and mouse spleen cells. Proc. Natl. Acad. Sci. USA 96:2256-61
117. Zorrilla EP, Sanchez-Alavez M, Sugama S, Brennan M, Fernandez R, et al. 2007. Interleukin-18 controls energy homeostasis by suppressing appetite and feed efficiency. Proc. Natl. Acad. Sci. USA 104:11097-102
118. Kim SH, Azam T, Novick D, Yoon DY, Reznikov LL, et al. 2002. Identification of amino acid residues critical for biological activity in human interleukin-18. J. Biol. Chem. 14:14
119. Novick D, Schwartsburd B, Pinkus R, Suissa D, Belzer I, et al. 2001. A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine 14:334-42
120. Tak PP, Bacchi M, Bertolino M. 2006. Pharmacokinetics of IL-18 binding protein in healthy volunteers and subjects with rheumatoid arthritis or plaque psoriasis. Eur. J. DrugMetab. Pharmacokinet. 31:109-16
121. Xiang Y, Moss B. 2001. Correspondence of the functional epitopes of poxvirus and human interleukin-18-binding proteins. J. Virol. 75:9947-54
122. Barton JL, Herbst R, Bosisio D, Higgins L, Nicklin MJ. 2000. A tissue specific IL-1 receptor antagonist homolog from the IL-1 cluster lacks IL-1, IL-1ra, IL-18 and IL-18 antagonist activities. Eur. J. Immunol. 30:3299-308
123. Debets R, Timans JC, Homey B, Zurawski S, Sana TR, et al. 2001. Two novel IL-1 family members, IL-1δ and IL-1ε, function as an antagonist and agonist of NF-κB activation through the orphan IL-1 receptor-related protein 2. J. Immunol. 167:1440-46
124. Towne JE, Garka KE, Renshaw BR, Virca GD, Sims JE. 2004. Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-κB and MAPKs. J. Biol. Chem. 279:13677-88
125. Busfield SJ, Comrack CA, Yu G, Chickering TW, Smutko JS, et al. 2000. Identification and gene organization of three novel members of the IL-1 family on human chromosome 2. Genomics 66:213-16
126. Kumar S, Hanning CR, Brigham-Burke MR, Rieman DJ, Lehr R, et al. 2002. Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-γ production. Cytokine 18:61-71
127. Pan G, Risser P, MaoW, Baldwin DT, Zhong AW, et al. 2001. IL-1H, an interleukin 1-related protein that binds IL-18 receptor/IL-1Rrp. Cytokine 13:1-7
128. Bufler P, Azam T, Gamboni-Robertson F, Reznikov LL, Kumar S, et al. 2002. A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity. Proc. Natl. Acad. Sci. USA 99:13723-28
129. Gao W, Kumar S, Lotze MT, Hanning C, Robbins PD, Gambotto A. 2003. Innate immunity mediated by the cytokine IL-1 homologue 4 (IL-1H4/IL-1F7) induces IL-12-dependent adaptive and profound antitumor immunity. J. Immunol. 170:107-13
130. Azam T, Novick D, Bufler P, Yoon DY, Rubinstein M, et al. 2003. Identification of a critical Ig-like domain in IL-18 receptor α and characterization of a functional IL-18 receptor complex. J. Immunol. 171:6574-80
131. Banda NK, Vondracek A, Kraus D, Dinarello CA, Kim SH, et al. 2003. Mechanisms of inhibition of collagen-induced arthritis by murine IL-18 binding protein. J. Immunol. 170:2100-5
132. Lewis EC, Dinarello CA. 2006. Responses of IL-18- and IL-18 receptor-deficient pancreatic islets with convergence of positive and negative signals for the IL-18 receptor. Proc. Natl. Acad. Sci. USA 103:16852-57
133. Gutcher I, Urich E, Wolter K, Prinz M, Becher B. 2006. Interleukin 18-independent engagement of interleukin 18 receptor-α is required for autoimmune inflammation. Nat. Immunol. 7:946-53
134. Nold MF, Nold-Petry CA, Zepp JA, Bufler P, Dinarello CA. 2008. The IL-1 family member IL-1F7 reduces innate immunity by inhibiting Toll-like receptor and IL-1 signaling pathways. Cytokine 43:264 (Abstr.)
135. Magne D, Palmer G, Barton JL, Mezin F, Talabot-Ayer D, et al. 2006. The new IL-1 family member IL-1F8 stimulates production of inflammatory mediators by synovial fibroblasts and articular chondrocytes. Arthritis Res. Ther. 8:R80
136. Lin H, Ho AS, Haley-Vicente D, Zhang J, Bernal-Fussell J, et al. 2001. Cloning and characterization of IL-1HY2, a novel interleukin-1 family member. J. Biol. Chem. 276:20597-602
137. Bensen JT, Dawson PA, Mychaleckyj JC, Bowden DW. 2001. Identification of a novel human cytokine gene in the interleukin gene cluster on chromosome 2q12-14. J. Interferon Cytokine Res. 21:899-904
138. Bergers G, Reikerstorfer A, Braselmann S, Graninger P, Busslinger M. 1994. Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membranebound proteins related to the IL-1 receptor. EMBO J. 13:1176-88
139. Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, Kastelein RA. 2007. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J. Immunol. 179:2551-55
140. Stevenson FT, Turck J, Locksley RM, Lovett DH. 1997. The N-terminal propiece of interleukin 1α is a transforming nuclear oncoprotein. Proc. Natl. Acad. Sci. USA 94:508-13
141. Wilson KC, Cruikshank WW, Center DM, Zhang Y. 2002. Prointerleukin-16 contains a functional CcN motif that regulates nuclear localization. Biochemistry 41:14306-12
142. Yang H,Wang H, Tracey KJ. 2001. HMG-1 rediscovered as a cytokine. Shock 15:247-53
143. Leung BP, Xu D, Culshaw S, McInnes IB, Liew FY. 2004. A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J. Immunol. 173:145-50
144. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. 2007. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J. Clin. Invest. 117:1538-49
145. Gadina M, Jefferies CA. 2007. IL-33: a sheep in wolf's clothing? Sci. STKE 2007:pe31
146. Miller AM, XuD, Asquith DL, Denby L, Li Y, et al. 2008. IL-33 reduces the development of atherosclerosis. J. Exp. Med. 205:339-46
147. Boraschi D, Tagliabue A. 2006. The interleukin-1 receptor family. Vitam. Horm. 74:229-54
148. Moritz D, Rodewald H-R, Gheyselinck J, Klemenz R. 1998. The IL-1 receptor-related T1 antigen is expressed on immature and mature mast cells and on fetal blood mast cell progenitors. J. Immunol. 161:4866-74
149. Parnet P, Garka KE, Bonnert TP, Dower SK, Sims JE. 1996. IL-1Rrp is a novel receptor-like molecule similar to the type I interleukin-1 receptor and its homologues T1/ST2 and IL-1R AcP. J. Biol. Chem. 271:3967-70
150. Torigoe K, Ushio S, Okura T, Kobayashi S, Taniai M, et al. 1997. Purification and characterization of the human interleukin-18 receptor. J. Biol. Chem. 272:25737-42
151. Born TL, Thomassen E, Bird TA, Sims JE. 1998. Cloning of a novel receptor subunit, AcPL, required for interleukin-18 signaling. J. Biol. Chem. 273:29445-50
152. Kim SH, Reznikov LL, Stuyt RJ, Selzman CH, Fantuzzi G, et al. 2001. Functional reconstitution and regulation of IL-18 activity by the IL- 18Rβ chain. J. Immunol. 166:148-54
153. Carrie A, Jun L, Bienvenu T, Vinet MC, McDonell N, et al. 1999. A new member of the IL-1 receptor family highly expressed in hippocampus and involved in X-linked mental retardation. Nat. Genet. 23:25-31
154. Sana TR, Debets R, Timans JC, Bazan JF, Kastelein RA. 2000. Computational identification, cloning, and characterization of IL-1R9, a novel interleukin-1 receptor-like gene encoded over an unusually large interval of human chromosome Xq22.2-q22.3. Genomics 69:252-62
155. Dimcheff DE, Volkert LG, Li Y, DeLucia AL, Lynch WP. 2006. Gene expression profiling of microglia infected by a highly neurovirulent murine leukemia virus: implications for neuropathogenesis. Retrovirology 3:26
156. Qin J, Qian Y, Yao J, Grace C, Li X. 2005. SIGIRR inhibits interleukin-1 receptor- andToll-like receptor 4-mediated signaling through different mechanisms. J. Biol. Chem. 280:25233-41
157. Huang X, Hazlett LD, Du W, Barrett RP. 2006. SIGIRR promotes resistance against Pseudomonas aeruginosa keratitis by down-regulating type-1 immunity and IL-1R1 and TLR4 signaling. J. Immunol. 177:548-56
158. Quiniou C, Sapieha P, Lahaie I, Hou X, Brault S, et al. 2008. Development of a novel noncompetitive antagonist of IL-1 receptor. J. Immunol. 180:6977-87
159. Anderson ME, Tejo BA, Yakovleva T, Siahaan TJ. 2006. Characterization of binding properties of ICAM-1 peptides to LFA-1: inhibitors of T-cell adhesion. Chem. Biol. Drug Des. 68:20-28
160. Ye K, Dinarello CA, Clark BD. 1993. Identification of the promoter region
161. Cullinan EB, Kwee L, Nunes P, Shuster DJ, Ju G, et al. 1998. IL-1 receptor accessory protein is an essential component of the IL-1 receptor. J. Immunol. 161:5614-20
162. Colotta F, Dower SK, Sims JE, Mantovani A. 1994. The type II "decoy" receptor: a novel regulatory pathway for interleukin-1. Immunol. Today 15:562-66
163. Neumann D, Kollewe C, Martin MU, Boraschi D. 2000. The membrane form of the type II IL-1 receptor accounts for inhibitory function. J. Immunol. 165:3350-57
164. Dinarello CA. 2005. The many worlds of reducing interleukin-1. Arthritis Rheum. 52:1960-67
165. Malinowsky D, Lundkvist J, Laye S, Bartfai T. 1998. Interleukin-1 receptor accessory protein interacts with the type II interleukin-1 receptor. FEBS Lett. 429:299-302
166. Smeets RL, Joosten LA, Arntz OJ, Bennink MB, Takahashi N, et al. 2005. Soluble interleukin-1 receptor accessory protein ameliorates collagen-induced arthritis by a different mode of action from that of interleukin-1 receptor antagonist. Arthritis Rheum. 52:2202-11
167. Drevlow BE, Lovis R, Haag MA, Sinacore JM, Jacobs C, et al. 1996. Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum. 39:257-65
168. Netea MG, Kullberg BJ, Boerman OC, Verschueren I, Dinarello CA, Van Der Meer JW. 1999. Soluble murine IL-1 receptor type I induces release of constitutive IL- 1α. J. Immunol. 162:4876-81
169. + release. Am. J. Physiol. Cell Physiol. 286:C1100-8